Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final first-in-human data for ...

Primary results from the Phase II ARACOG (AFT-47) trial, a head-to-head randomized trial conducted by Alliance Foundation Trials LLC, showed that patients treated with NUBEQA ® (darolutamide; n=55) ...

Discover the essential techniques for validating and cleaning JSON data, ensuring data integrity and proper formatting for various applications and APIs.

New research shows a novel pill is helping people with advanced pancreatic cancer live longer. It's not a cure, as the drug's effects eventually waned. But it's a very different ...